

University of Alabama at Birmingham Coagulation Therapeutic Ranges and Reference Intervals	
Monitoring Heparin and Coumadin: Therapeutic Ranges	
Anti-Xa heparin assay: therapeutic low MW heparin, U/mL	0.5 — 1
Anti-Xa heparin assay: prophylactic low MW heparin, U/mL	0.2 — 0.4
Anti-Xa heparin assay: therapeutic unfractionated heparin, U/mL	0.3 — 0.7
Anti-Xa heparin assay: prophylactic unfractionated heparin, U/mL	0.1 — 0.4
PT Coumadin most applications, INR	2 — 3
PT Coumadin, mechanical heart valves, INR	2.5 — 3.5
PTT unfractionated heparin, Sec	92 — 125
PTT unfractionated prophylactic subcutaneous heparin, Sec	60 — 92
Screening Test Reference Intervals	
PT, Sec	12.6 — 15
PT, INR	1 — 1
PTT, Sec	25 — 35
TCT, Sec	0 — 21
Factor Assay Reference Intervals	
Fibrinogen, mg/dL	220 — 498
II, %	50 — 150
V, %	50 — 150
VII, %	50 — 150
VIII, %	50 — 186
vWF activity (ristocetin cofactor), %	50 — 166
vWF antigen, %	50 — 249
IX, %	50 — 150
X, %	50 — 150
XI, %	50 — 150
XII, %	50 — 150
HMWK (Fitzgerald), %	65 — 135
PK (Fletcher), %	65 — 135
XIII by urea solubility	Decr — Nor
Control Protein Reference Intervals	
Antithrombin, %	78 — 126
Protein C, %	70 — 140
Protein S, %	65 — 140
Other Assays	
Activated protein C resistance, ratio	<1.8 —
Anti-cardiolipin Antibody IgG, GPL	0 — 12
Anti-cardiolipin Antibody IgM, MPL	0 — 10
D-dimer, ng/mL	110 — 240
Euglobulin clot lysis time, hours	2 — 6
Reptilase time, ratio	< 1.3